trending Market Intelligence /marketintelligence/en/news-insights/trending/e0lxzzflpoygyfgemllegw2 content esgSubNav
In This List

Roche's cervical cancer test receives US FDA approval for expanded use

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Infographic

Infographic: The Big Picture 2023 Sustainability Outlook

Blog

The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism


Roche's cervical cancer test receives US FDA approval for expanded use

Roche Holding AG said the U.S. Food and Drug Administration approved the expanded use of its cobas test as a primary screening for cervical cancer in women 25 and older.

The Switzerland-based pharmaceutical giant said its test is the only human papillomavirus, or HPV, test approved for use as a primary screening with the SurePath and ThinPrep PreservCyt Solution — the two types of liquid media used to collect samples for the vast majority of Pap and HPV tests in the U.S.

Roche said that following the FDA decision, the cobas HPV test is now approved for all cervical cancer screening uses that are supported by professional society guidelines.

The cobas HPV test received its first FDA approval in 2014 for primary cervical cancer screening without an accompanying Pap test.